Neurosyphilis risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{Neurosyphilis}} | {{Neurosyphilis}} | ||
{{CMG}}; {{AE}}{{MMJ}} | {{CMG}}; {{AE}}{{MMJ}} | ||
== Overview == | ==Overview== | ||
The most potent risk factor in the development of | The most potent risk factor in the development of tabes dorsalis is [[HIV AIDS|HIV infection]]. Other risk factors include: Male gender, high serum [[Rapid plasma reagent|RPR titer]], advanced age, and African American race. | ||
== Risk Factors == | ==Risk Factors== | ||
The most potent risk factor in the development of | *The most potent risk factor in the development of tabes dorsalis is [[HIV AIDS|HIV infection]]. Other risk factors include: Male gender, high serum [[Rapid plasma reagent|RPR titer]], advanced age, and African American race. | ||
===Common Risk Factors=== | |||
*Common risk factors in the development of tabes dorsalis may be occupational, environmental, genetic, and viral. | |||
*Common risk factors in the development of tabes dorsalis include:<ref name="pmid15175987">{{cite journal| author=Vidal-Bermúdez JE, Bonasser-Filho F, Schiavon-Nogueira R| title=[Syphilitic meningomyelitis in a patient with AIDS]. | journal=Rev Neurol | year= 2004 | volume= 38 | issue= 10 | pages= 998-9 | pmid=15175987 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15175987 }} </ref><ref name="pmid26660338" /> | |||
**[[HIV AIDS|HIV infection]] | |||
**Male patients | |||
**High serum [[Rapid plasma reagent|rapid plasma reagent titer]] | |||
== | ===Less Common Risk Factors=== | ||
*Less common risk factors in the development of tabes dorsalis include:<ref name="pmid26660338">{{cite journal| author=Shi M, Peng RR, Gao Z, Zhang S, Lu H, Guan Z et al.| title=Risk profiles of neurosyphilis in HIV-negative patients with primary, secondary and latent syphilis: implications for clinical intervention. | journal=J Eur Acad Dermatol Venereol | year= 2016 | volume= 30 | issue= 4 | pages= 659-66 | pmid=26660338 | doi=10.1111/jdv.13514 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26660338 }} </ref> | |||
**Advanced age | |||
**African American race | |||
[[Category: | ==References== | ||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category: (name of the system)]] | |||
Revision as of 17:35, 5 March 2018
|
Neurosyphilis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neurosyphilis risk factors On the Web |
|
American Roentgen Ray Society Images of Neurosyphilis risk factors |
|
Risk calculators and risk factors for Neurosyphilis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
The most potent risk factor in the development of tabes dorsalis is HIV infection. Other risk factors include: Male gender, high serum RPR titer, advanced age, and African American race.
Risk Factors
- The most potent risk factor in the development of tabes dorsalis is HIV infection. Other risk factors include: Male gender, high serum RPR titer, advanced age, and African American race.
Common Risk Factors
- Common risk factors in the development of tabes dorsalis may be occupational, environmental, genetic, and viral.
- Common risk factors in the development of tabes dorsalis include:[1][2]
- HIV infection
- Male patients
- High serum rapid plasma reagent titer
Less Common Risk Factors
- Less common risk factors in the development of tabes dorsalis include:[2]
- Advanced age
- African American race
References
- ↑ Vidal-Bermúdez JE, Bonasser-Filho F, Schiavon-Nogueira R (2004). "[Syphilitic meningomyelitis in a patient with AIDS]". Rev Neurol. 38 (10): 998–9. PMID 15175987.
- ↑ 2.0 2.1 Shi M, Peng RR, Gao Z, Zhang S, Lu H, Guan Z; et al. (2016). "Risk profiles of neurosyphilis in HIV-negative patients with primary, secondary and latent syphilis: implications for clinical intervention". J Eur Acad Dermatol Venereol. 30 (4): 659–66. doi:10.1111/jdv.13514. PMID 26660338.